The first thing that striked me as long term follower and investor in the company is the subtle sense of courage, aspiration and pride communicated by management when I was reading their annual reports
Yes there are two reports this time. In this post I will discuss Suven Pharamaceuticals and then will do a subsequent one on Suven Life Sciences. I have covered the company extensively and if you are new to the company then there is plenty of reading material here
Performance
The company has stopped given breakdown of research projects in various phases and prodding in concall also didn’t help to get this information out from management. This was a very interesting piece of data and as it provided us insight on their product mix. Also company has merged CRAMS revenue with Commercial Supplies so they are not available as seperate figures like last year
Segment (INR Crores) | 31-Mar-2019 | 31-Mar-2020 | Growth |
CDMO | 379 | 468 | 23.48% |
Spec Chem | 216 | 304 | 40.74% |
Technical Services | 50 | 70 | 40.00% |
Total | 645 | 842 | 30.54% |
Rest of men dislikes visiting a physician first before ordering Kamagra Checking expiry date viagra india prices on the pack and also take necessary precautions. After all, IEP … Read the rest